285 related articles for article (PubMed ID: 17437208)
1. Embryo-fetal toxicity signals for 17alpha-hydroxyprogesterone caproate in high-risk pregnancies: a review of the non-clinical literature for embryo-fetal toxicity with progestins.
Christian MS; Brent RL; Calda P
J Matern Fetal Neonatal Med; 2007 Feb; 20(2):89-112. PubMed ID: 17437208
[TBL] [Abstract][Full Text] [Related]
2. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
EFSA GMO Panel Working Group on Animal Feeding Trials
Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
[TBL] [Abstract][Full Text] [Related]
3. Analysis of the nonsteroidal anti-inflammatory drug literature for potential developmental toxicity in rats and rabbits.
Cook JC; Jacobson CF; Gao F; Tassinari MS; Hurtt ME; DeSesso JM
Birth Defects Res B Dev Reprod Toxicol; 2003 Feb; 68(1):5-26. PubMed ID: 12852480
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the teratogenic potential of delalutin (17 alpha-hydroxyprogesterone caproate) in mice.
Seegmiller RE; Nelson GW; Johnson CK
Teratology; 1983 Oct; 28(2):201-8. PubMed ID: 6648824
[TBL] [Abstract][Full Text] [Related]
5. The safety of progesterone and 17-hydroxyprogesterone caproate administration for the prevention of preterm birth: an evidence-based assessment.
O'Brien JM
Am J Perinatol; 2012 Oct; 29(9):665-72. PubMed ID: 22773279
[TBL] [Abstract][Full Text] [Related]
6. The use of progestational agents for preterm birth: lessons from a mouse model.
Elovitz MA; Mrinalini C
Am J Obstet Gynecol; 2006 Oct; 195(4):1004-10. PubMed ID: 17000233
[TBL] [Abstract][Full Text] [Related]
7. Teratogen update: evaluation of the reproductive and developmental risks of caffeine.
Christian MS; Brent RL
Teratology; 2001 Jul; 64(1):51-78. PubMed ID: 11410911
[TBL] [Abstract][Full Text] [Related]
8. Analysis of reproductive toxicity and classification of glufosinate-ammonium.
Schulte-Hermann R; Wogan GN; Berry C; Brown NA; Czeizel A; Giavini E; Holmes LB; Kroes R; Nau H; Neubert D; Oesch F; Ott T; Pelkonen O; Robert-Gnansia E; Sullivan FM
Regul Toxicol Pharmacol; 2006 Apr; 44(3 Suppl 1):S1-76. PubMed ID: 16510221
[TBL] [Abstract][Full Text] [Related]
9. Different embryo-fetal toxicity effects for three VLA-4 antagonists.
Crofts F; Pino M; DeLise B; Guittin P; Barbellion S; Brunel P; Potdevin S; Bergmann B; Hofmann T; Lerman S; Clark RL
Birth Defects Res B Dev Reprod Toxicol; 2004 Apr; 71(2):55-68. PubMed ID: 15098199
[TBL] [Abstract][Full Text] [Related]
10. Progesterone for prevention of recurrent preterm birth: impact of gestational age at previous delivery.
Spong CY; Meis PJ; Thom EA; Sibai B; Dombrowski MP; Moawad AH; Hauth JC; Iams JD; Varner MW; Caritis SN; O'Sullivan MJ; Miodovnik M; Leveno KJ; Conway D; Wapner RJ; Carpenter M; Mercer B; Ramin SM; Thorp JM; Peaceman AM; Gabbe S;
Am J Obstet Gynecol; 2005 Sep; 193(3 Pt 2):1127-31. PubMed ID: 16157124
[TBL] [Abstract][Full Text] [Related]
11. Embryotoxicity of sex steroidal hormones in nonhuman primates: II. Hydroxyprogesterone caproate, estradiol valerate.
Hendrickx AG; Korte R; Leuschner F; Neumann BW; Poggel A; Binkerd P; Prahalada S; Günzel P
Teratology; 1987 Feb; 35(1):129-36. PubMed ID: 3563931
[TBL] [Abstract][Full Text] [Related]
12. Maternal toxicity: a possible etiological factor in embryo-fetal deaths and fetal malformations of rodent-rabbit species.
Khera KS
Teratology; 1985 Feb; 31(1):129-53. PubMed ID: 3983854
[TBL] [Abstract][Full Text] [Related]
13. Uterine activity in women receiving 17 alpha-hydroxyprogesterone caproate for the prevention of preterm birth: an observational study.
O'Brien JM; Ho SJ; Istwan NB; Stanziano GJ; Rhea DJ; Barton JR
Am J Perinatol; 2010 Feb; 27(2):157-62. PubMed ID: 19644788
[TBL] [Abstract][Full Text] [Related]
14. Final amended report on the safety assessment of Methylparaben, Ethylparaben, Propylparaben, Isopropylparaben, Butylparaben, Isobutylparaben, and Benzylparaben as used in cosmetic products.
Int J Toxicol; 2008; 27 Suppl 4():1-82. PubMed ID: 19101832
[TBL] [Abstract][Full Text] [Related]
15. Meta-analysis of randomized controlled trials comparing 17α-hydroxyprogesterone caproate and vaginal progesterone for the prevention of recurrent spontaneous preterm delivery.
Oler E; Eke AC; Hesson A
Int J Gynaecol Obstet; 2017 Jul; 138(1):12-16. PubMed ID: 28369874
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological use of progesterone and 17-alpha-hydroxyprogesterone caproate in the prevention of preterm delivery.
Facchinetti F; Vaccaro V
Minerva Ginecol; 2009 Oct; 61(5):401-9. PubMed ID: 19749671
[TBL] [Abstract][Full Text] [Related]
17. 17alpha-hydroxyprogesterone caproate for the prevention of preterm delivery: A cost-effectiveness analysis.
Odibo AO; Stamilio DM; Macones GA; Polsky D
Obstet Gynecol; 2006 Sep; 108(3 Pt 1):492-9. PubMed ID: 16946206
[TBL] [Abstract][Full Text] [Related]
18. Does progesterone treatment influence risk factors for recurrent preterm delivery?
Meis PJ; Klebanoff M; Dombrowski MP; Sibai BM; Leindecker S; Moawad AH; Northen A; Iams JD; Varner MW; Caritis SN; O'Sullivan MJ; Miodovnik M; Leveno KJ; Conway D; Wapner RJ; Carpenter M; Mercer B; Ramin SM; Thorp JM; Peaceman AM; Gabbe S
Obstet Gynecol; 2005 Sep; 106(3):557-61. PubMed ID: 16135587
[TBL] [Abstract][Full Text] [Related]
19. The role of progesterone in maternal and fetal medicine.
Di Renzo GC; Giardina I; Clerici G; Mattei A; Alajmi AH; Gerli S
Gynecol Endocrinol; 2012 Nov; 28(11):925-32. PubMed ID: 23057618
[TBL] [Abstract][Full Text] [Related]
20. In an in-vitro model using human fetal membranes, 17-α hydroxyprogesterone caproate is not an optimal progestogen for inhibition of fetal membrane weakening.
Kumar D; Moore RM; Mercer BM; Mansour JM; Mesiano S; Schatz F; Lockwood CJ; Moore JJ
Am J Obstet Gynecol; 2017 Dec; 217(6):695.e1-695.e14. PubMed ID: 29031893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
